The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)

Inclusion Criteria: * Male or female subjects aged ≥ 18 * Eye disease for which a primary vitrectomy is indicated * Best Corrected Visual Acuity (BCVA) of 20/800 or better in the non-study eye * Written informed consent obtained from the subject prior to inclusion in the trial Exclusion Criteria: * Proliferative diabetic retinopathy. * Subjects with any vitreous hemorrhage or any other vitreous opacification which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either Optical Coherence Tomography (OCT) and/or fluorescein angiogram in the study eye * Aphakia in the study eye * High myopia (more than 8D) in study eye (unless prior cataract extraction or refractive surgery that makes refraction assessment unreliable for myopia severity approximation, in which case axial length \>28 mm is an exclusion). * Subjects with history of rhegmatogenous retinal detachment in the either eye * Subjects who have had ocular surgery, laser photocoagulation treatment, or intravitreal injection(s) in the study eye in the prior three months * Subjects who have had laser photocoagulation to the macula in the study eye at any time * Subjects with uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 26 mm Hg in spite of treatment with anti-glaucoma medication) * Subjects with a history of uveitis in either eye. * Subjects who are pregnant or of child-bearing potential not utilizing an acceptable form of contraception. Acceptable methods of birth control include intrauterine device, oral, implanted, or injected contraceptives, and barrier methods with spermicide. * Subjects who, in the Investigators view, will not complete all visits and investigations * Subjects who have participated in an investigational drug trial within the past 30 days * Subjects who have previously participated in this trial